Fig. 12From: Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer modelTime-integrated activity ratios (dimensionless) a tumor to blood (TIA-tumor/TIA-blood), b tumor to kidney (TIA-tumor/TIA-kidney), and c tumor to liver (TIA-tumor/TIA-liver) for 225Ac-, 212Pb-, and 211At-labeled anti-PD-L1-BC for the 1.0, 3.0, and 10 mg/kg protein concentrationsBack to article page